Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 261,929 319,053 656,089
Total Sell Value $13,270,852 $22,448,451 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 20 27 56
End Date 2024-03-21 2023-12-19 2023-06-20 2022-06-20

   
Records found: 1303
  Page 49 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-07-05 4 AS $18.21 $36,582 D/D (2,000) 8,695     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-07-02 4 AS $18.09 $227,203 D/D (12,500) 10,000     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-07-02 4 OE $4.00 $50,000 D/D 12,500 22,500     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-06-25 4 AS $17.65 $44,125 D/D (2,500) 10,695     -
   Wood Mark VP, Human Resources   •       –      –    2007-06-07 4 AS $17.54 $18,332 D/D (1,045) 0     -
   Wood Mark VP, Human Resources   •       –      –    2007-06-07 4 OE $6.13 $9,446 D/D 1,045 1,045     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-06-04 4 AS $18.38 $45,962 D/D (2,500) 13,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-06-01 4 AS $18.18 $183,293 D/D (10,000) 13,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-06-01 4 OE $6.46 $64,600 D/D 10,000 25,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-05-21 4 AS $18.54 $37,123 D/D (2,000) 15,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-05-03 4 AS $16.70 $251,807 D/D (15,000) 17,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-05-03 4 OE $6.46 $96,900 D/D 15,000 32,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-05-02 4 AS $16.36 $24,647 D/D (1,500) 15,142     -
   Davis George Eric VP, General Counsel   •       –      –    2007-04-30 4 B $5.19 $13,517 D/D 2,607 2,607 2.74     -
   Baffi Robert SVP, Technical Operations   •       –      –    2007-04-30 4 B $5.19 $13,917 D/D 2,684 33,124 2.74     -
   Aselage Steve SVP, Global Commercial Dev   •       –      –    2007-04-30 4 B $6.92 $14,295 D/D 2,066 4,895 2.74     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-04-30 4 AB $6.92 $17,664 D/D 2,553 17,695     -
   Kakkis Emil D Chief Medical Officer   •       –      –    2007-04-30 4 B $5.19 $15,462 D/D 2,982 94,126 2.74     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-04-04 4 AS $17.70 $116,163 D/D (6,500) 16,642     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-04-04 4 OE $6.46 $32,300 D/D 5,000 21,642     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-04-02 4 AS $17.18 $216,305 D/D (12,500) 10,000     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-04-02 4 OE $4.00 $50,000 D/D 12,500 22,500     -
   Klein Joseph III Director   –       •      –    2007-03-07 4 S $16.36 $196,397 I/I (12,000) 0     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-03-02 4 AS $16.44 $24,723 D/D (1,500) 18,142     -
   Davis George Eric VP, General Counsel   •       –      –    2007-02-22 4 S $18.37 $238,865 D/D (13,000) 0     -
  1303 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 49 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us